Fig. 4: IBD distributions by treatment and time to recurrence in a randomized controlled trial conducted in Ethiopia.
From: Microhaplotype deep sequencing assays to capture Plasmodium vivax infection lineages
a presents the IBD distributions in initial and recurrent infection pairs across all pairs and grouped by treatment arm; AL (Artemether-Lumefantrine), CQ (Chloroquine), AL + PQ (AL + Primaquine) and CQ + PQ. Each treatment is presented with a different colour. b presents the same IBD data grouped by recurrences occurring less versus more than 120 days after the initial infection. Each boxplot presents the median, interquartile range and minimum and maximum value. Data are presented on recurrence pairs from 128 independent patients, with only one infection pair presented per patient to avoid potential bias (n = 128 patients, 256 samples). Majority (90%, 115/128) of pairs reflect day 0 and recurrence 1 time points. Where the day 0 or recurrence 1 infections failed genotyping or had inconclusive clinical metadata, consecutive pairs of recurrence 2 to 4 pairs were used instead as the patients received the same treatment up to recurrence 4.
